Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer.
Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wikström P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quigley DA, Lang JM, Zhao SG, Sjöström M.Mol Oncol. 2025 Feb 22. doi: 10.1002/1878-0261.70001. Online ahead of print.PMID: 39985777
Neoadjuvant SBRT plus Elective Nodal Irradiation with Concurrent Capecitabine for Patients with Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 Trial.
Basree MM, Witt JS, Uboha NV, Lubner M, Minter R, Weber S, Ronnekleiv-Kelly S, Abbott D, Kratz J, Patel M, Zafar SN, LoConte N, Lubner SJ, Deming D, Ritter MA, Mohindra P, Bassetti MF.Pract Radiat Oncol. 2025 Feb 7:S1879-8500(25)00011-6. doi: 10.1016/j.prro.2025.01.011. Online ahead of print.PMID: 39924052
Primer on disability: Why accessibility is important for all medical physicists.
Jones LE, Eliason G, Gupta S, Jeong EG, Besemer A, Sterling DA, Fagerstrom JM.J Appl Clin Med Phys. 2025 Feb 9:e70003. doi: 10.1002/acm2.70003. Online ahead of print.PMID: 39924939
An ultra-high dose rate Bragg peak tracking technique provides more affordable proton radiotherapy for cancer patients: From principle to experimental validation.
Wei S, Lin H, Cheng C, Choi JI, Simone CB 2nd, Kang M.Radiother Oncol. 2025 Feb 21;206:110800. doi: 10.1016/j.radonc.2025.110800. Online ahead of print.PMID: 39988304
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.
Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG.Ann Oncol. 2025 Feb 13:S0923-7534(25)00025-0. doi: 10.1016/j.annonc.2025.01.017. Online ahead of print.PMID: 39986927
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT.Eur Urol Oncol. 2025 Feb 6:S2588-9311(25)00002-1. doi: 10.1016/j.euo.2025.01.002. Online ahead of print.PMID: 39920014